JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML.